AXGN
NASDAQAxogen Inc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$43.36-0.38 (-0.88%)
01:30 PM01:45 PM
News · 26 weeks44-93%
2025-12-142026-06-07
Mix1990d
- Insider9(47%)
- Other4(21%)
- SEC Filings3(16%)
- Earnings1(5%)
- Leadership1(5%)
- Offering1(5%)
Latest news
25 items- PRThe Newest Name on Nasdaq Wants to Help the Body Rebuild ItselfIssued on behalf of Conexeu Sciences Inc.A biotech debut out of Reno is betting that the next wave of medicine won't replace tissue — it'll grow it back.NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in medicine. The premise is no longer to put something foreign into the body when tissue is lost. The premise is to give the body the scaffolding, the cues, and the conditions it needs to grow back what was taken — and then have that scaffolding dissolve, leaving only the patient's own living tissue behind.On May 21, 2026, a new Nasdaq ticker put a public-mark
- INSIDERDirector Wendell Amy Mcbride exercised 1,647 shares at a strike of $14.85 and sold $70,162 worth of shares (1,647 units at $42.60) (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Johnson John sold $477,968 worth of shares (11,050 units at $43.26) and exercised 11,050 shares at a strike of $7.04 (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERDirector Weiler Kathy Johnson exercised 16,344 shares at a strike of $6.95 and sold $720,623 worth of shares (16,344 units at $44.09) (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERChief Marketing Officer Kemp Jens sold $173,761 worth of shares (4,000 units at $43.44), decreasing direct ownership by 5% to 72,451 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERCFO Hartley Lindsey Marie sold $45,897 worth of shares (1,051 units at $43.67) and exercised 5,463 shares at a strike of $8.24, increasing direct ownership by 7% to 65,146 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSales VP Quackenbush Doris sold $168,720 worth of shares (3,878 units at $43.51), decreasing direct ownership by 4% to 92,416 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERNew insider Quackenbush Doris claimed ownership of 96,294 shares (SEC Form 3)3 - Axogen, Inc. (0000805928) (Issuer)
- PRTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
- PRAxogen, Inc. to Participate in the 2026 Bank of America Global Healthcare ConferenceALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming 2026 Bank of America Global Healthcare Conference. Axogen's management is scheduled to present on Wednesday, May 13, 2026, at 9:35 AM PT. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at ir.axogeninc.com. About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development and commercializ
- SECSEC Form DEF 14A filed by Axogen Inc.DEF 14A - Axogen, Inc. (0000805928) (Filer)
- SECSEC Form 10-Q filed by Axogen Inc.10-Q - Axogen, Inc. (0000805928) (Filer)
- SECAxogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Axogen, Inc. (0000805928) (Filer)
- PRAxogen, Inc. Reports First Quarter 2026 Financial ResultsALACHUA, Fla. and TAMPA, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026. First Quarter Financial Results First quarter 2026 revenue was $61.5 million, a 26.6% increase compared to first quarter 2025 revenue of $48.6 million. Gross margin was 75.2% for the first quarter of 2026, compared to 71.9% in the first quarter of 2025. Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, compared to $3.8 million, or $0.08 per sha
- PRCVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsMINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical device industry, and I'm excited for him to join our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "His extensive experience leading high growth organizations, both as an executi
- PRAxogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026ALACHUA, Fla. and TAMPA, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the first quarter of 2026 on Tuesday, April 28, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may dial toll-free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, an archived replay, and presentation slides from the event are available
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Axogen Inc.SCHEDULE 13G/A - Axogen, Inc. (0000805928) (Subject)
- INSIDERSEC Form 4 filed by Devinney Erick Wayne4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Hartley Lindsey Marie4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERChief Marketing Officer Kemp Jens was granted 50,670 shares and covered exercise/tax liability with 18,366 shares, increasing direct ownership by 73% to 76,451 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERChief Innovation Officer Devinney Erick Wayne was granted 33,780 shares and covered exercise/tax liability with 21,978 shares, increasing direct ownership by 5% to 252,934 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDEREVP & General Counsel Began Marc A converted options into 11,250 shares, was granted 33,780 shares and covered exercise/tax liability with 13,180 shares, increasing direct ownership by 174% to 50,135 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERCFO Hartley Lindsey Marie was granted 17,453 shares and covered exercise/tax liability with 6,630 shares, increasing direct ownership by 24% to 55,276 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Dale Michael D4 - Axogen, Inc. (0000805928) (Issuer)
- INSIDERCFO Hartley Lindsey Marie covered exercise/tax liability with 6,704 shares and was granted 17,500 shares, increasing direct ownership by 32% to 44,453 units (SEC Form 4)4 - Axogen, Inc. (0000805928) (Issuer)
AXGN FAQ
6 questionsWhat does Axogen Inc. do?
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged...Where does AXGN stock trade?
Axogen Inc. (AXGN) is listed on NASDAQ.What sector and industry is AXGN in?
Axogen Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about AXGN?
Axogen Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $4000.00 price target on 2026-02-19. Recent price targets range from $1300.00 to $4000.00.What companies are similar to AXGN?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare AXGN side-by-side with any of them on Quantisnow.How can I track AXGN on Quantisnow?
Quantisnow aggregates Axogen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXGN to receive live email and push alerts on every new disclosure.